Docirbrutinib is an investigational new drug that is being evaluated for the treatment of cancer. It is a selective Bruton's tyrosine kinase (BTK) inhibitor that targets chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.